Fundraising FoxThe Column Group — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)inJared Rutter(Founder)John Tallarico(Founder)Ralph DeBerardinis(Founder)
Co-investorsLux CapitalRA CapitalNextech Invest
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Board seatJohn JoseyJames EvangelistaPeter Svennilson· per SEC Form D
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalMission Biocapital+4 more
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inDaniel Becker(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersViking GlobalAccess IndustriesRA Capital
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsATEL VenturesB3 HoldingNextech InvestSoftBank Vision Fund8VCCasdin Capital+1 more
Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Eric Betzig(Founder)Luke Lavis(Founder)Robert Tjian(Founder)Xavier Darzacq(Founder)
Co-investorsEcoR1 CapitalGeneral CatalystHorizons VenturesLux CapitalTCG CrossoverWPSS Investments+1 more
.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.